Bayer

Life-extending cancer and heart therapies

Leverkusen, North Rhine-Westphalia, Germany

Bayer is a multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, with operations in over 80 countries. It operates through three main business divisions: Pharmaceuticals, Crop Science, and Consumer Health. Bayer is investing significantly in digital transformation, including hundreds of AI-driven initiatives across drug discovery, clinical trials, and healthcare applications.

Shareable draft

Check out Bayer on @MedStartr Today Bayer is a multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, with operations in over 80 countries. It operates through three main business divisions: Pharmaceuticals, Crop Science, and Consumer Health. Bayer is investing significantly in digital transformation, including hundreds of AI-driven initiatives across drug discovery, clinical trials, and healthcare applications. #WomenSHealthcare #Hematology #Ophthalmology #NeurologyRareDiseases #Immunology #PainRelief #ColdAndFlu #DigestiveHealth #Dermatology #NutritionalSupplements #Allergies #MentalBehavioralHealth #CardiovascularDisease #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/QtqiqSRFohI

Get Involved in Bayer

How We Help

Core Technology

Cell and gene therapy platforms, precision medicine, pharmacogenetics, biomarkers, chemoproteomics, PROTACs, RNA-targeting small molecules, artificial intelligence, machine learning, big data, diagnostic imaging, advanced biotechnology, digital agriculture platforms, integrated seed and chemical offerings.

Key Differentiators

deployed generative AI for drug discovery including hypothesis generation and regulatory documentation automation; implemented AI for clinical trial planning and analysis; launched heart risk assessment tool powered by Huma; partnered with Google Cloud to develop AI solutions for radiologists

Clinical Focus

Cardiovascular diseases, oncology, women's healthcare, hematology, ophthalmology, neurology & rare diseases, immunology, as well as consumer health areas like pain relief, allergy, cold and flu, digestive health, dermatology, and nutritional supplements.

Target Customers

Consumers, patients, farmers, healthcare professionals, pharmacies, hospitals.

Product Stage

Mature

Company Info

Business Model: B2B, B2C (multifaceted across pharmaceuticals, consumer health, and crop science)
Founded: 1863
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.bayer.com

Disease Areas

Women's Healthcare Hematology Ophthalmology Neurology & Rare Diseases Immunology Pain Relief Cold and Flu Digestive Health Dermatology Nutritional Supplements Allergies Mental Health Cardiovascular Disease Cancer & Oncology

Technologies

Precision Medicine TechCell and Gene TherapyPharmacogeneticsBiomarkersChemoproteomicsPROTACsRNA-targeting Small MoleculesMachine LearningBig DataMedical ImagingDiagnostic ImagingAdvanced BiotechnologyDigital AgricultureData ScienceGenerative AIAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

FDA approvals: Kerendia (heart failure, CKD/T2D), Nubeqa (prostate cancer - 46% progression reduction), Hyrnuo (HER2+ lung cancer accelerated), Lynkuet (menopause), Gadoquatrane (MRI contrast Japan first approval). Phase III ARANOTE, FINEARTS-HF, FIDELIO-DKD completed.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Bayer?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.